Strike Bio RNAi Cancer Treatment Patent Application EP3134528A1
Summary
The European Patent Office published patent application EP3134528A1 titled 'Multiple Targeted RNAi for the Treatment of Cancers' on April 15, 2026. The applicants are Strike Bio, Inc. and Baylor College of Medicine, both based in the United States. The invention covers RNAi-based therapeutics targeting multiple genes for cancer treatment, with the application designating 34 European member states including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.
About this source
GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 49 changes logged to date.
What changed
The EPO published patent application EP3134528A1 for a method of treating cancers using multiple targeted RNA interference (RNAi) technology. The application names five inventors and lists Strike Bio, Inc. and Baylor College of Medicine as applicants. The designated states include all 34 EPO member states spanning the European Union and additional European countries. Affected parties include pharmaceutical and biotechnology companies developing RNAi-based cancer therapeutics, as they should monitor this application to assess potential freedom-to-operate implications in European markets. The publication of the A1 application initiates the formal examination period during which third parties may file observations.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MULTIPLE TARGETED RNAI FOR THE TREATMENT OF CANCERS
Publication EP3134528A1 Kind: A1 Apr 15, 2026
Applicants
Strike Bio, Inc., Baylor College of Medicine
Inventors
RAO, Donald, NEMUNAITIS, John, O'MALLEY, Bert, W., LONARD, David
IPC Classifications
C12N 15/113 20100101AFI20171102BHEP A61K 48/00 20060101ALI20171102BHEP C12N 5/10 20060101ALI20171102BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.